These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38316077)

  • 1. Phospho-Tau 181 quantification method for Alzheimer's disease based on an array 2D biosensor combined with surface plasmon resonance imaging.
    Oldak L; Zielinska Z; Socha K; Bogdan S; Gorodkiewicz E
    Talanta; 2024 May; 271():125736. PubMed ID: 38316077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Nanoplasmonic Biosensor for Ultrasensitive Detection of Alzheimer's Disease Biomarker Using a Chaotropic Agent.
    Kim H; Lee JU; Kim S; Song S; Sim SJ
    ACS Sens; 2019 Mar; 4(3):595-602. PubMed ID: 30747516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface plasmon resonance biosensors for detection of Alzheimer's biomarkers; an effective step in early and accurate diagnosis.
    Rezabakhsh A; Rahbarghazi R; Fathi F
    Biosens Bioelectron; 2020 Nov; 167():112511. PubMed ID: 32858422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Poly(allylamine) coated layer-by-layer assembly decorated 2D carbon backbone for highly sensitive and selective detection of Tau-441 using surface plasmon resonance biosensor.
    Nangare S; Patil P
    Anal Chim Acta; 2023 Aug; 1271():341474. PubMed ID: 37328252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biosensing: The best alternative for conventional methods in detection of Alzheimer's disease biomarkers.
    Mobed A; Hasanzadeh M
    Int J Biol Macromol; 2020 Oct; 161():59-71. PubMed ID: 32504710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers.
    Kim H; Lee JU; Song S; Kim S; Sim SJ
    Biosens Bioelectron; 2018 Mar; 101():96-102. PubMed ID: 29054022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of an SPRi Test for the Quantitative Detection of Cadherin 12 in Human Plasma and Peritoneal Fluid.
    Oldak L; Lukaszewski Z; Leśniewska A; Goławski K; Laudański P; Gorodkiewicz E
    Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoarchitectured Bioconjugates and Bioreceptors Mediated Surface Plasmon Resonance Biosensor for
    Nangare S; Patil P
    Crit Rev Anal Chem; 2022; 52(5):1139-1169. PubMed ID: 33426916
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease.
    Kurz C; Stöckl L; Schrurs I; Suridjan I; Gürsel SÜ; Bittner T; Jethwa A; Perneczky R
    J Neurochem; 2023 Apr; 165(1):95-105. PubMed ID: 36625424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new tetra-plex fluorimetric assay for the quantification of cerebrospinal fluid β-amyloid42, total-tau, phospho-tau and α-synuclein in the differential diagnosis of neurodegenerative dementia.
    Diaz-Lucena D; Escaramis G; Villar-Piqué A; Hermann P; Schmitz M; Varges D; Santana I; Del Rio JA; Martí E; Ferrer I; Baldeiras I; Zerr I; Llorens F
    J Neurol; 2020 Sep; 267(9):2567-2581. PubMed ID: 32372181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma-based diagnostic and screening platform using a combination of biosensing signals in Alzheimer's disease.
    Kim HJ; Kim H; Park D; Yoon DS; San Lee J; Hwang KS
    Biosens Bioelectron; 2023 Jun; 230():115246. PubMed ID: 37003061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct plasma phosphorylated-tau proteins profiling for the differential diagnosis of mild cognitive impairment and Alzheimer's disease by plasmonic asymmetric nanobridge-based biosensor.
    Kim S; Ma X; Jeon MJ; Song S; Lee JS; Lee JU; Lee CN; Choi SH; Sim SJ
    Biosens Bioelectron; 2024 Apr; 250():116085. PubMed ID: 38295582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-positive patient identification.
    Barthélemy NR; Bateman RJ; Hirtz C; Marin P; Becher F; Sato C; Gabelle A; Lehmann S
    Alzheimers Res Ther; 2020 Mar; 12(1):26. PubMed ID: 32183883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma Phospho-Tau Identifies Alzheimer's Co-Pathology in Patients with Lewy Body Disease.
    Hall S; Janelidze S; Londos E; Leuzy A; Stomrud E; Dage JL; Hansson O
    Mov Disord; 2021 Mar; 36(3):767-771. PubMed ID: 33285015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
    Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
    Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An SPRi-based biosensor pilot study: Analysis of multiple circulating extracellular vesicles and hippocampal volume in Alzheimer's disease.
    Picciolini S; Gualerzi A; Carlomagno C; Cabinio M; Sorrentino S; Baglio F; Bedoni M
    J Pharm Biomed Anal; 2021 Jan; 192():113649. PubMed ID: 33038641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
    Palmqvist S; Tideman P; Cullen N; Zetterberg H; Blennow K; ; Dage JL; Stomrud E; Janelidze S; Mattsson-Carlgren N; Hansson O
    Nat Med; 2021 Jun; 27(6):1034-1042. PubMed ID: 34031605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid pathology but not APOE ε4 status is permissive for tau-related hippocampal dysfunction.
    Düzel E; Ziegler G; Berron D; Maass A; Schütze H; Cardenas-Blanco A; Glanz W; Metzger C; Dobisch L; Reuter M; Spottke A; Brosseron F; Fliessbach K; Heneka MT; Laske C; Peters O; Priller J; Spruth EJ; Ramirez A; Speck O; Schneider A; Teipel S; Kilimann I; Jens W; Schott BH; Preis L; Gref D; Maier F; Munk MH; Roy N; Ballarini T; Yakupov R; Haynes JD; Dechent P; Scheffler K; Wagner M; Jessen F
    Brain; 2022 May; 145(4):1473-1485. PubMed ID: 35352105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanomaterial-based Optical and Electrochemical Biosensors for Amyloid beta and Tau: Potential for early diagnosis of Alzheimer's Disease.
    Phan LMT; Hoang TX; Vo TAT; Pham HL; Le HTN; Chinnadayyala SR; Kim JY; Lee SM; Cho WW; Kim YH; Choi SH; Cho S
    Expert Rev Mol Diagn; 2021 Feb; 21(2):175-193. PubMed ID: 33560154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.